Nasus Pharma Ltd. (NSRX) Price & Analysis

22 Followers

NSRX Stock Chart & Stats

$2.24

Market closed

$2.24

Day’s Range― - ―

52-Week Range$1.98 - $9.99

Previous CloseN/A

VolumeN/A

Average Volume (3M)2.05K

Market Cap

$26.82M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.47

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding8,612,906

10 Day Avg. Volume1,204

30 Day Avg. Volume2,049

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-1.39

Revenue Forecast (FY)N/A

Nasus Pharma Ltd. News

Nasus Pharma Advances Intranasal Ondansetron After Positive Preclinical Data

The latest update is out from Nasus Pharma Ltd. ( ($NSRX) ). Nasus Pharma Ltd., a clinical-stage intranasal...

1M ago

NSRX

Nasus Pharma price target lowered to $18 from $19 at Citizens

Citizens lowered the firm’s price target on Nasus Pharma (NSRX) to $18 from $19 and keeps an Outperform...

4M ago

NSRX

Nasus Pharma Moves Intranasal Epinephrine Toward Pivotal Trial After Positive Phase 2 Results

Nasus Pharma Ltd. ( ($NSRX) ) has provided an announcement. Nasus Pharma Ltd., a clinical-stage developer of intranasal...

4M ago

NSRX

Nasus Pharma advances NS002 to pivotal study following Phase 2 results

Nasus Pharma (NSRX) provided a business update highlighting recent Phase 2 results for NS002, its intranasal powder epinephrine...

4M ago

NSRX

Nasus Pharma’s NS002 Demonstrates Consistent Early Advantage in Epinephrine Delivery (NYSE: NSRX)

WSW, NY, March 19th, 2026, FinanceWire For decades, the treatment of anaphylaxis has been built around a single...

4M ago

SER

NSRX

Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform

WSW, NY, March 16th, 2026, FinanceWire For decades, the treatment of life-threatening allergic reactions has been defined by...

4M ago

CTMX

NSRX

Nasus Pharma’s NS002 Outperforms EpiPen in Phase 2 Anaphylaxis Study, Pivotal Trial Planned for Late 2026

Nasus Pharma Ltd. ( ($NSRX) ) has shared an update. On March 16, 2026, Nasus Pharma reported positive...

4M ago

NSRX

Nasus Pharma announces topline data from Phase 2 clinical study of NS002

Nasus Pharma (NSRX) announced top line results from its Phase 2 clinical study of NS002, the Company’s investigational...

4M ago

NSRX

Nasus Pharma Shareholders Approve Capital Increase and Amended Articles at March 5 Meeting

The latest announcement is out from Nasus Pharma Ltd. ( ($NSRX) ). On March 5, 2026, Nasus Pharma...

4M ago

NSRX

Nasus Pharma Moves March 5 Shareholder Meeting to Virtual-Only Format Amid Israel Security Situation

The latest update is out from Nasus Pharma Ltd. ( ($NSRX) ). Nasus Pharma Ltd. announced on March...

4M ago

NSRX

Nasus Pharma files to sell 5.39M ordinary shares for holders

17:31 EST Nasus Pharma (NSRX) files to sell 5.39M ordinary shares for holders Published first on TheFly –...

4M ago

NSRX

Nasus Approaches Key Data Readout That Could Reshape the Multi Billion Dollar Epinephrine Market (NYSE: NSRX)

WSW, NY, March 2nd, 2026, FinanceWire Epinephrine is the standard treatment for anaphylaxis, and its effectiveness is not...

4M ago

NSRX

XERS

Nasus Pharma Files Updated Corporate Presentation With SEC

Nasus Pharma Ltd. ( ($NSRX) ) has issued an announcement. On February 23, 2026, Nasus Pharma Ltd. announced...

5M ago

NSRX

Nasus Pharma Ltd trading resumes

10:27 EST Nasus Pharma (NSRX) Ltd trading resumes Published first on TheFly – the ultimate source for real-time,...

5M ago

NSRX

NSRX FAQ

What was Nasus Pharma Ltd.’s price range in the past 12 months?

Nasus Pharma Ltd. lowest stock price was $1.98 and its highest was $9.99 in the past 12 months.

What is Nasus Pharma Ltd.’s market cap?

Nasus Pharma Ltd.’s market cap is $26.82M.

When is Nasus Pharma Ltd.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Nasus Pharma Ltd.’s earnings last quarter?

Currently, no data Available

Is Nasus Pharma Ltd. overvalued?

According to Wall Street analysts Nasus Pharma Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nasus Pharma Ltd. pay dividends?

Nasus Pharma Ltd. does not currently pay dividends.

What is Nasus Pharma Ltd.’s EPS estimate?

Nasus Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nasus Pharma Ltd. have?

Nasus Pharma Ltd. has 8,612,906 shares outstanding.

What happened to Nasus Pharma Ltd.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Nasus Pharma Ltd.?

Currently, no hedge funds are holding shares in NSRX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nasus Pharma Ltd.

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.